

PRIOR AUTHORIZATIONS AND UPDATES IN THE LOGISTICS
OF PRESCRIBING BIOLOGICS AS AN EMBEDDED
DEPARTMENTAL PHARMACIST

Lauren Pheasant, PharmD, BCACP

1

OBJECTIVES

- Define the role of a clinical pharmacist in a dermatology practice
- Review strategies to help streamline the prior authorization process for biologic medications
- Recognize opportunities to make medications more affordable for patients


2

BACKGROUND

- MTDM (medication therapy disease management) Pharmacist at Geisinger Health System
- Work under a collaborative practice agreement
- Fully embedded supporting Danville location
- Virtual support to multiple off-site clinics across the system


3

THE ROLE OF THE PHARMACIST



4

THE ROLE OF THE PHARMACIST



5

DRUG PROCUREMENT

1. Medication approval
2. Affordable co-payments
3. Specialty pharmacy coordination

6

THE ROLE OF THE PHARMACIST

- Drug procurement
- Initial medication and disease counseling
- Ongoing clinical monitoring
- Side effect management
- Vaccine coordination
- Medication adherence
- Drug information

7

COUNSELING

- Dosing
- Side effects
- Expectations
- Storage
- Administration
- Drug interactions
- Pregnancy/breastfeeding
- Missed Doses
- Misc: Vaccines, surgery, illness

MEDICATION GUIDE DRUG-X [drug X] (drugimab-cznm) injection, for intramuscular use
What is the most important information I should know about DRUG-X?
What is DRUG-X?
Who should not take DRUG-X?
Before taking DRUG-X, tell your healthcare provider about all of your medical conditions, including if you:
How should I take DRUG-X?
What should I avoid while taking DRUG-X?
What are the possible side effects of DRUG-X?
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store DRUG-X?
General information about the safe and effective use of DRUG-X.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use DRUG-X for a condition for which it was not prescribed. Do not give DRUG-X to other people, even if they have the same symptoms that you have. It may harm them.
You can ask your pharmacist or healthcare provider for information about DRUG-X that is written for health professionals.
What are the ingredients in DRUG-X?
Active ingredients:
Inactive ingredients:
Manufactured for:
Manufactured by:
This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised: MM/YYYY

8

THE ROLE OF THE PHARMACIST

- Drug procurement
- Initial medication and disease counseling
- Ongoing clinical monitoring
- Side effect management
- Vaccine coordination
- Medication adherence
- Drug information

9

THE ROLE OF THE PHARMACIST

- Drug procurement
- Initial medication and disease counseling
- Ongoing clinical monitoring
- Side effect management
- Vaccine coordination
- Medication adherence
- Drug information

10

PRIOR AUTHORIZATIONS

11

“According to the 2020 AAD Prior Authorization Survey, assigned staff spend up to 3.5 hours each day doing prior authorizations. Additionally, of the 25% of patients who are put into the prior authorization process each day, only half are successful in the process.”

Navigating Prior Authorizations in Dermatology – Prior Authorization training. (2023, January 25). Retrieved September 6, 2023, from <https://www.priorauthtraining.org/dermatology-medication-costs-and-prior-authorization/>

“Patients with complex dermatological conditions experience a median delay of 12 days.”

Jew OS, Okawa J, Barbieri JS, McCaffrey J, Hayward E, Werth VP. Evaluating the effect of prior authorizations in patients with complex dermatologic conditions. *J Am Acad Dermatol.* 2020;83(6):1674-1680. doi:10.1016/j.jaad.2020.06.996.



“Psoriasis drugs are driving autoimmune market growth, with sales of over \$40 billion expected by 2031.”

IQVIA Institute for Human Data Science. Dermatology Drives Autoimmune Market Growth. *iqvia.com*. Accessed January 21, 2023. <https://www.iqvia.com/-/media/iqvia/pdfs/library/articles/iqvia-forecast-link-autoimmune-market-article.pdf>

“The Journal of Cutaneous Medicine showed the recently approved IL-23 inhibitor guselkumab to have an annual cost of \$101,536”

Jashin J, Wu MD, Steven R, Feldman MD, Shjira Rastogi PhD, MBA, et al. “Comparison of the Cost-Effectiveness of Biologic Drugs Used for Moderate-to-Severe Psoriasis Treatment in the United States,” *Journal of Dermatological Treatment.* May 7, 2018

12

STREAMLINING THE PROCESS

- Proactive vs. reactive
- Documentation
- Formularies
- Lab work
- Tools/resources available

13

PROACTIVE APPROACH

- High cost medications
 - Complete prior authorization ahead of time before prescribing
 - Less back and fourth with pharmacy
 - Fewer scripts sent

14

DOCUMENTATION

- Use smart sets/smart phrases
- Measurable outcomes
 - Examples: BSA, IGA, special sites involved, etc
- Medications tried/failed
- Medications they cannot use and why
- Side effects counseled on
- Will not use with "..."
- Lab work
- Vaccines

15

FORMULARIES

- Keep a document of common formularies and requirements
- Familiarize yourself with the Pennsylvania Preferred Drug List (PDL) for Medicaid
- Use previous authorizations as guidance

16

CYTOKINE AND CAM ANTAGONISTS

Preferred Agents	Non-Preferred Agents
Actemra (<i>tocilizumab</i>) Syringe ^{PA, QL}	Actemra (<i>tocilizumab</i>) Actpen ^{QL}
Actemra (<i>tocilizumab</i>) Vial ^{PA, QL}	Arcalyst (<i>nilonacept</i>) Vial ^{QL}
Avsola (<i>infliximab-axxq</i>) Vial ^{PA}	Cimzia (<i>certolizumab pegol</i>) Syringe ^{QL}
Enbrel (<i>etanercept</i>) Mini Cartridge ^{PA, QL}	Cosentyx (<i>secukinumab</i>) Pen ^{QL}
Enbrel (<i>etanercept</i>) Sureclick Pen ^{PA, QL}	Cosentyx (<i>secukinumab</i>) Syringe ^{QL}
Enbrel (<i>etanercept</i>) Syringe ^{PA, QL}	Entyvio (<i>vedolizumab</i>) Vial ^{QL}
Enbrel (<i>etanercept</i>) Vial ^{PA, QL}	Ilaris (<i>canakinumab</i>) Vial ^{QL}
Humira (<i>adalimumab</i>) Pen ^{PA, QL}	Ilumya (<i>tildrakizumab</i>) Syringe ^{QL}
Humira (<i>adalimumab</i>) Syringe ^{PA, QL}	Inflectra (<i>infliximab-dyyb</i>) Vial
Infliximab Vial (<i>Janssen's unbranded infliximab</i>) ^{PA}	Kezvara (<i>sarilumab</i>) Pen ^{QL}
Kineret (<i>anakinra</i>) Syringe ^{PA}	Kezvara (<i>sarilumab</i>) Syringe ^{QL}
Orencia (<i>abatacept</i>) Clickjet ^{PA, QL}	Olumiant (<i>baricitinib</i>) Tablet ^{QL}
Orencia (<i>abatacept</i>) Vial ^{PA, QL}	Orencia (<i>abatacept</i>) Syringe ^{QL}
Otezla (<i>apremilast</i>) Tablet ^{PA, QL}	Remicade (<i>infliximab</i>) Vial
Simponi (<i>golimumab</i>) Pen ^{PA, QL}	Renflexis (<i>infliximab-abda</i>) Vial
Simponi (<i>golimumab</i>) Syringe ^{PA, QL}	Rinvoq ER (<i>upadacitinib</i>) Tablet ^{QL}
Taltz (<i>ixekizumab</i>) Autoinjector ^{PA, QL}	Siliq (<i>brodalumab</i>) Syringe ^{QL}
Taltz (<i>ixekizumab</i>) Syringe ^{PA, QL}	Simponi Aria (<i>golimumab</i>) Vial
Xeljanz (<i>tofacitinib</i>) Tablet ^{PA, QL}	Skyrizi (<i>risankizumab</i>) On-Body Injector ^{QL}
	Skyrizi (<i>risankizumab</i>) Pen ^{QL}
	Skyrizi (<i>risankizumab</i>) Syringe ^{QL}
	Stelara (<i>ustekinumab</i>) Syringe ^{QL}
	Stelara (<i>ustekinumab</i>) Vial ^{QL}
	Tremfya (<i>guselkumab</i>) Autoinjector ^{QL}
	Tremfya (<i>guselkumab</i>) Syringe ^{QL}
	Xeljanz (<i>tofacitinib</i>) Solution ^{QL}

Pennsylvania Medical Assistance Statewide Preferred Drug List (PDL) |
 Pennsylvania Medical Assistance Preferred Drug List. (n.d.).
<https://papdl.com/preferred-drug-list>

17

TOOLS/RESOURCES

- Electronic prior authorization systems (Examples: CoverMyMeds, SureScripts, PromptPa, PriorAuthNow)
- Using letter of medical necessity templates
 - AAD
 - Drug manufactures
 - Disease foundations (Example: HS foundations)

Darves B. Dealing with prescription prior authorization in dermatology – practical dermatology. Accessed January 21, 2023. <https://practicaldermatology.com/articles/2019-mar/dealing-with-prescription-prior-authorization-in-dermatology>

18

APPEALS

- Submit literature
- Use letter of medical necessity templates
- Understand next steps/options (peer to peer, 1st level appeal, 2nd level appeal)
- Patient vs. physician initiated appeals and forms required

19

MEDICATION COSTS

20

Commercial/Marketplace

Medicaid

Medicare

Uninsured

21

COMMERCIAL/MARKETPLACE INSURANCE

- Co-pay cards
- Debit cards
- Plan exclusions

22

MEDICARE

- Manufacture free drug programs
- PACE/PACENET
- Coverage Gap

STAGE 1	STAGE 2	STAGE 3	STAGE 4
<p>Annual Deductible \$0 - \$505</p> <p>If you have a deductible, you pay 100% of your drug cost until you reach the deductible amount set by your plan.</p>	<p>Initial Coverage \$506 - \$4,660</p> <p>You pay a copay or percentage for your medication and your plan covers the rest of the retail cost for your covered prescription drugs.</p>	<p>Coverage Gap or "The Donut Hole" \$4,661 - \$7,400</p> <p>In this stage, you pay a greater share of the prescription costs. You pay 25% of the cost for covered brand-name drugs and 25% of cost for covered generic drugs.</p>	<p>Catastrophic Coverage \$7,401 +</p> <p>You pay the greater of 5% of cost or \$0.38 copay for brand-name medications and \$4.15 copay for generic medications for the rest of the year.</p>

<https://www.retired.com/library/articles/what-part-d-donut-hole-and-why-does-it-matter>

23



"THE PENNSYLVANIA
LOTTERY BENEFITS OLDER
AMERICANS"

24

PACE AND PACENET PROGRAMS

Eligibility Requirements:

- 65 years or older
- PA resident 90+ days
- Cannot be enrolled into Medicaid
- Meet income guidelines

Based on a 30-day supply:

PACE : \$6 Generic and \$9 Brand

PACENET: \$8 Generic and \$15 Brand

2023 Income Guidelines:

PACE:

Single: \$14,500 or less

Married: \$17,700 or less

PACENET:

Single: between \$14,500 and \$33,500

Married: \$17,700 and \$41,500

Department of Aging. (n.d.). PACE Prescription assistance. Pennsylvania Department of Aging. <https://www.aging.pa.gov/aging-services/prescriptions/Pages/default.aspx>

25

UNINSURED

- Manufacture free drug programs
- Possible Medicaid enrollment
- Foundations

26

PATIENT ASSISTANCE RESOURCES

- NeedyMeds
- RxAssist
- The Medicine Assistance tool
- Drug manufacture websites
- PAN foundation

27

ACKNOWLEDGEMENTS

- Geisinger Pharmacy team
- Geisinger Dermatology department
- Pennsylvania Academy of Dermatology and Dermatologic Surgery

28

REFERENCES

Navigating Prior Authorizations in Dermatology – Prior Authorization training. (2023, January 25). Retrieved September 6, 2023, from <https://www.priorauthtraining.org/dermatology-medication-costs-and-prior-authorization/>

IQVIA Institute for Human Data Science. Dermatology Drives Autoimmune Market Growth. Iqvia.com. Accessed January 21, 2023. <https://www.iqvia.com/-/media/iqvia/pdfs/library/articles/iqvia-forecast-link-autoimmune-market-article.pdf>

Jew OS, Okawa J, Barbieri JS, McCaffrey J, Hayward E, Werth VP. Evaluating the effect of prior authorizations in patients with complex dermatologic conditions. *J Am Acad Dermatol.* 2020;83(6):1674-1680. doi:10.1016/j.jaad.2020.06.998.

Petitt CE, Kiracofe E, Adamson A, Barbieri JS. Prior authorizations in dermatology and impact on patient care: An updated survey of US dermatology providers and staff by the American Academy of Dermatology. *Dermatol Online J.* 2021;27(1):13030/qt990631n9. Published 2021 Jan 15.

Pennsylvania Medical Assistance Statewide Preferred Drug List (PDL) | Pennsylvania Medical Assistance Preferred Drug List. (n.d.). <https://papdl.com/preferred-drug-list>

Darves B. Dealing with prescription prior authorization in dermatology – practical dermatology. Accessed January 21, 2023. <https://practicaldermatology.com/articles/2019-mar/dealing-with-prescription-prior-authorization-in-dermatology>

Department of Aging. (n.d.). PACE: Prescription assistance. Pennsylvania Department of Aging. <https://www.aging.pa.gov/aging-services/prescriptions/Pages/default.aspx>

29

PRIOR AUTHORIZATIONS AND UPDATES IN THE LOGISTICS OF PRESCRIBING BIOLOGICS AS AN EMBEDDED DEPARTMENTAL PHARMACIST

Lauren Pheasant, PharmD, BCACP

30